To evaluate the number of metastatic cervical cancer patients who had an adequate response to chemotherapy to be eligible for consolidative chemoradiation and subsequent outcomes, including overall survival and disease-free intervals.
Key Findings:
38 patients met inclusion criteria, with 84% having squamous cell histology.
All patients received platinum-based chemotherapy; 53% received consolidative chemoradiation.
Patients who received chemoradiation had a median treatment-free interval of 13.7 months (IQR 5.3-36.5) and 35% had no evidence of disease at last follow-up.
Overall survival for patients receiving chemoradiation was 26.7 months (IQR 16.8-55.9), while those not eligible had a median survival of 14 months (IQR 9.1-17.6).
Factors associated with progression on first line chemotherapy included prescription for pain medications and anticoagulation prior to treatment.
Interpretation:
Limitations:
Retrospective nature of the study may limit the generalizability of the findings.
Small sample size may affect the robustness of the results.
